The #1 prescribed NOAC across
the continuum of care*1
The patients they studied are the ones I see.
AMONG NOACs:
Most real-world experience: more than 2.5 million patients prescribed
in the US.2
Most safety data generated in clinical trials in patients
studied with high risk of thrombotic events.†3-16
Most affordable: the lowest average
out-of-pocket cost.17
Not intended to be a comparison of safety
or efficacy outcomes.
*Hospital, Long-Term Care, Retail.
†
Based on the following: CHADS2 scores 3-6 in ROCKET AF (N=12,402), ARISTOTLE
(N=5502), ENGAGE-AF (N=~11,200), and RE-LY (N=5882); risk factors of DVT, PE,
DVT/PE, cancer, elderly, previous VTE, provoked VTE, unprovoked VTE, and recent
trauma or surgery in EINSTEIN pooled analysis (N=8281), AMPLIFY (N=5395),
Hokusai-VTE (N=8240), and RE-COVER I and II (N=5107).
IMPORTANT SAFETY INFORMATION
WARNING: (A) PREMATURE DISCONTINUATION OF
XARELTO® INCREASES THE RISK OF THROMBOTIC
EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
A. PREMATURE DISCONTINUATION OF XARELTO®
INCREASES THE RISK OF THROMBOTIC EVENTS
Premature discontinuation of any oral anticoagulant,
including XARELTO®, increases the risk of thrombotic
events. If anticoagulation with XARELTO® is
discontinued for a reason other than pathological
bleeding or completion of a course of therapy,
consider coverage with another anticoagulant.
B. SPINAL/EPIDURAL HEMATOMA
Epidural or spinal hematomas have occurred in
patients treated with XARELTO® who are receiving
neuraxial anesthesia or undergoing spinal puncture.
These hematomas may result in long-term or
permanent paralysis. Consider these risks when
scheduling patients for spinal procedures.
Factors that can increase the risk of developing
epidural or spinal hematomas in these patients include:
Use of indwelling epidural catheters
Concomitant use of other drugs that affect
hemostasis, such as non-steroidal anti-inflammatory
drugs (NSAIDs), platelet inhibitors, other
anticoagulants, see Drug Interactions
A history of traumatic or repeated epidural or
spinal punctures
A history of spinal deformity or spinal surgery
Optimal timing between the administration of
XARELTO® and neuraxial procedures is not known
Monitor patients frequently for signs and symptoms
of neurological impairment. If neurological compromise
is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial
intervention in patients anticoagulated or to be
anticoagulated for thromboprophylaxis.
NOAC = non-vitamin K oral anticoagulant; CHADS2 = congestive heart failure, hypertension, age ≥75 years,
diabetes mellitus, prior stroke or transient ischemic attack; DVT = deep vein thrombosis; PE = pulmonary embolism;
VTE = venous thromboembol